▼ Objectives: The aim of this study was to determine what variables predict a ' combined treatment outcome' (COMBOUT) in patients with chronic schizophrenia. Methods: This analysis (n = 522) was based on a randomized, double-blind, fl exible-dose, 12-week study that enrolled chronically-ill patients diagnosed with schizophrenia or a related disorder. COMBOUT was assessed using the PANSS for symptoms, CGI-S for overall clinical status, MADRS for depressive symptoms, QLS for functioning/QOL, and SWN-K for subjective wellbeing. Possible predictors included demographics as well as baseline scores (Model I), and early change (week 2) scores (Model II).
Introduction
▼ Improvement in psychopathology has been shown to occur relatively early during antipsychotic drug therapy in patients with schizophrenia [ 1 , 2 ] , and to predict subsequent treatment outcomes [ 3 -8 ] . In these studies, treatment outcomes have been defi ned in terms of a percent reduction in psychopathology as assessed by various effi cacy scales. However, 'real-world outcomes' involve not only improvement in symptoms, but also improvement in psychosocial and occupational functioning [ 9 ] and in patient's self-perception [ 10 ] . A recent study has demonstrated early improvement within 2 weeks across multiple outcome domains including those assessing the patient's functioning, quality of life and subjective well-being [ 11 ] . Regarding these diff erent outcome domains, how relevant are baseline values in predicting overall treatment outcomes?, and is early improvement for one domain particularly relevant for outcome in general? Recently, Lambert et al. [ results from a 3-month, observational study designed, in part, to assess the role of clinician-rated measures and subjective wellbeing at baseline as predictors of a 'combined outcome criterion' inclusive of endpoint scores on symptomatology, functioning and subjective well-being. Their fi ndings demonstrated that, while all response categories were signifi cantly associated with the 'combined outcome criterion', subjective well-being and social functioning demonstrated the greatest predictive value. Using related constructs but with diff erent measurement scales and inclusion of the assessment of depressive symptoms, the objective of this study was to determine what variables predict a ' combined treatment outcome' (COMBOUT) in patients with schizophrenia. COMBOUT was defi ned as a combination of endpoint scores on measures of psychopathology, depressive symptoms, functioning/QOL and subjective well-being. Possible predictors included demographics, baseline and early change scores of these 5 domains as well as of extrapyramidal symptoms.
Patients and Methods

▼
Study design
This analysis was based on a randomized, double-blind, fl exibledosed, parallel 12-week study enrolling 628 patients to explore the relationship between early response to an antipsychotic medication and subsequent improvement in psychopathology (primary outcome measure) using the oral atypical antipsychotic risperidone. The analysis focused on 522 patients who entered the third study period and were treated for up to 12 weeks (as described below). Patients met diagnostic criteria for schizophrenia, schizoaff ective disorder or schizophreniform disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). After complete description of the study was given to patients, written informed consent was obtained. In addition, the study was approved by the ethics committee from each Institution in which it was conducted. Patient confi dentiality was not breached, and the study was done in accordance with the Declaration of Helsinki. The primary manuscript from this clinical trial describes in detail the overall study design, inclusion/exclusion criteria, and concomitant medications [ 6 ] . In brief, there were 3 Study Periods (SP): SPI, screening, SPII, study enrollment in which all patients were treated with risperidone (2-6 mg/day) during the initial 2 weeks, SPIII, early responder status was assessed (response defi ned as achieving ≥ 20 % reduction in PANSS total score), with early responders (N = 144) continuing on risperidone (2-6 mg/day) for 10 additional weeks and early nonresponders randomized (1:1) to either stay on risperidone (N = 192; dose range: 2-6 mg/day) or switch to olanzapine (N = 186; dose range:10-20 mg/day) for 10 additional weeks of treatment. Patients had to be at least moderately ill at the start of the study and experiencing an exacerbation of their illness within the 2 weeks preceding visit 1 that led to an intensifi cation of the level of psychiatric care.
Measures
The Positive and Negative Syndrome Scale (PANSS) [ 13 ] was used to assess the patients' psychopathology, the Clinical Global Impressions -Severity Scale (CGI-S) [ 14 ] to assess the overall clinical severity of the disease, the Montgomery-Asberg Depression Rating Scale (MADRS) [ 15 ] to assess depressive symptoms, the Quality Of Life Scale (QLS) [ 16 ] and the Schizophrenia Objective Functioning Index (SOFI) [ 17 ] to assess overall functioning, and the Subjective Well-Being On Neuroleptics -Short Form Scale (SWN-K) [ 18 ] to assess subjective well-being. In addition, the Simpson-Angus Scale [ 19 ] was used to assess parkinsonian symptoms, the Barnes Akathisia Scale [ 20 ] to assess akathisia, and the Abnormal Involuntary Movement Scale (AIMS) [ 14 ] to assess tardive dyskinesia.
The 'combined outcome criterion'
COMBOUT at week 12 included PANSS total, CGI-S, MADRS total, QLS total and SWN-K total scores. The PANSS and CGI-S were measured at every visit. MADRS, QLS and SWN-K were measured at visit 1 (baseline), 4 (week 2), 7 (week 6), and 9 (week 12). For each scale, the last non-missing observation in study period III (visits 5-9) was used to calculate COMBOUT. Each scale was transformed, and as necessary reversed, into measures ranging from 0-100 according to the methodology in [ 21 ] , with higher scores refl ecting a better outcome. COMBOUT is the summation of those equally weighted 5 transformed measures, with a range from 0-500. If one of the 5 transformed measures was missing, then COMBOUT was treated as missing.
Statistical methodology
Baseline demographic characteristics and disease state were summarized as mean ± standard deviation (SD) for continuous variables, and number of counts and percentages for categorical variables. The non-parametric sign tests were applied to test mean changes in PANSS, CGI-S, QLS, MADRS, and SWN-K from baseline to week 2 and endpoint at week 12. 2 linear regression models were adopted to predict the COMBOUT at week 12. In the fi rst model, we investigated whether baseline scores of PANSS, CGI-S, MADRS, QLS, and SWN-K are predictors of COM-BOUT. In the second model, we studied whether the early changes in those 5 scales from baseline to week 2 can be predictive of COMBOUT. A 2-tailed α level of 0.05 was applied to all the hypothesis tests. All analyses were performed using statistical software (SAS Drug Development; SAS Institute Inc, Cary, NC).
Results
▼
Patients' characteristics • ▶ Table 1 summarizes the demographics and disease state of the 522 patients at baseline. Patients were predominantly male (61.7 %) with an average age of 41.9 years. There was an equal distribution of patients who were Caucasian (44.8 %) and those who were of African descent (44.8 %).
Dosing
The overall mean dose (from visit 5 to 9) was 4.78 mg/day for the early-responders treated with risperidone, 5.04 mg/day for the early non-responders treated with risperidone, and 17.26 mg/ day for the early non-responders who were treated with risperidone for the fi rst 2 weeks and then switched to olanzapine.
Changes observed in individual measures
At endpoint (week 12), 87 % (n = 456) of patients had non-missing values of COMBOUT with a mean of 338.4 (SD 54.7, range 156.1-477.5). The normality test indicated that COMBOUT was normally distributed. For mean changes from baseline to week 2, This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
and from baseline to week 12, the sign test showed highly signifi cant changes across all scales measured ( • ▶ Table 2 ).
Relationships between outcome domains
The Pearson's correlation coeffi cients among all measures at baseline and at week 2 are shown in • ▶ Table 3 . All correlations were signifi cant. The highest correlation coeffi cients were observed between the QLS and SOFI (at baseline, r = 0.662, p < 0.001; at week 2, r = 0.732, p < 0.001), indicating that the QLS and SOFI are highly correlated and likely measuring similar constructs. As a consequence, the QLS was used as a measure in calculating and predicting COMBOUT.
Other comparisons at baseline revealed moderate correlations between the PANSS total score and scores for the CGI-S (r = 0.447; p < 0.001), QLS (r = − 0.391; p < 0.001) and SOFI (r = − 0.417; p < 0.001). Correlations between the PANSS total score and scores on the MADRS (r = 0.271; p < 0.001) and SWN-K (r = − 0.193; p < 0.001) were substantially lower. Interestingly, the highest correlation coeffi cient observed for the MADRS was the SWN-K (r = − 0.390; p < 0.001) and similarly, the highest correlation coeffi cient observed for the SWN-K was the MADRS (r = − 0.496; p < 0.001). In general, the correlation coeffi cients were larger at week 2, with the exception of the correlation coeffi cient observed between the PANSS total and SOFI which was slightly smaller at week 2 compared to baseline.
Predicting COMBOUT at 3 months
We adopted 2 linear regression analyses (models) to predict COMBOUT at endpoint ( • ▶ For the QLS, a separate analysis incorporating its 4 subscale scores revealed that patients with higher QLS interpersonal relations (p < 0.001) and instrumental role (p = 0.022) subscale scores had signifi cantly greater COMBOUT scores at endpoint. Race (ethnicity) was not a signifi cant predictor of COMBOUT (p = 0.052). However, a breakdown analysis showed that Caucasians had signifi cantly higher (p = 0.008) COMBOUT scores at week 12 than African Americans. All other variables were not found to be predictive of COMBOUT in Model I. The R-square was 0.287. The model diagnostic showed that both the normality and constant-variance assumptions were met.
Model II (mean change at week 2 using total scores; controlled for baseline): Out of the 522 patients, 76 % (n = 398) had complete data. The 398 subjects included in Model II had a signifi cantly higher SWN-K total score at baseline (p = 0.032) than the 124 subjects who did not enter the model. No other diff erences in baseline characteristics were observed between these 2 groups. The results showed that an early reduction in the PANSS total score (T = − 2.32; p = 0.021) or CGI-S score (T = − 2.22; p = 0.027), or an early increase in the QLS score (T = 4.93; p < 0.001) or SWN-K score (T = 3.88; p < 0.001) led to a significantly higher COMBOUT at endpoint. The early change in MADRS did not predict COMBOUT. Using PANSS factor scores for positive and negative symptoms, we found that early change in the PANSS positive factor score (p = 0.047), but not the PANSS negative factor score, was signifi cantly associated with COMBOUT. All other variables were not found to be predictive of COMBOUT in Model II. The R-square was 0.546. The model diagnostic showed that both the normality and constant-variance assumptions were met.
Discussion
▼
In this study, we investigated the predictive power of several domains (baseline and improvement at week 2) on 12 week ' combined treatment outcome' (COMBOUT) in patients with schizophrenia. Possible predictors included demographics, baseline scores and early change scores for psychopathology, functioning/quality of life, subjective well-being, and extrapyramidal symptoms. In the fi rst regression analysis (Model I), which focused on baseline variables, COMBOUT was predicted by a lower level of depressive symptoms, and better expert-rated quality of life (social and occupational functioning). In the second regression analysis (Model II), which focused on early change, COMBOUT was predicted mostly by increases in QLS and SWN-K, followed by decreases in PANSS and CGI-S at week 2. EPS variables were not predictors of COMBOUT in either model tested.
A number of reports in the literature have highlighted global measures of mental, occupational, and psychosocial functioning (e. g., Global Assessment of Functioning, useful work/QLS instrumental role domain, Medical Outcomes Study-Short Form 36-Item Health Survey) at the start of a study as predictors of subsequent treatment outcomes [ 22 -24 ] . The current fi ndings with the QLS total score, and specifi cally with the interpersonal and instrumental (occupational) domains, are consistent with these prior fi ndings. Similarly, we also observed lower baseline depressive symptoms to be predictive of a better ' combined treatment outcome' . These results agree with previous research, patients with more severe depressive symptoms have been reported to have worse treatment outcomes [ 25 , 26 ] , although some studies have suggested otherwise [ 23 , 27 , 28 ] . The discrepancy might be explained by a number of factors, infl uencing the occurrence and course of depressive symptoms in schizophrenia (such as patient's age, severity of positive, negative and cognitive symptoms, patient population, particularly acute vs. stable, institutionalized vs. non-institutionalized) [ 28 ] . Numerous long-term studies have indicated that of the diff erent psychopathological domains, higher depressive symptoms are most strongly associated with lower QOL [ 29 -32 ] , and lower subjective well-being [ 33 , 34 ] in patients with schizophrenia. Lambert et al. [ 12 ] had previously reported negative symptoms and CGI-S scores at baseline as predictive of a combined treatment outcome at 3 months. We did not fi nd the PANSS total or CGI-S scores at baseline to be predictive of COMBOUT. Given that the PANSS total score was not predictive of COMBOUT, we conducted additional analyses on the PANSS positive or negative factor scores, which were also not predictive of COMBOUT (data not shown). Diff erences between the 2 studies may underlie these disparate fi ndings, including that patients in the Lambert et al. study were all diagnosed with schizophrenia, had higher baseline CGI-S scores and lower SWN-K scores, used amisulpiride as the antipsychotic agent, and reported somewhat diff erent measures for the PANSS. Early change at week 2 across a broad array of outcome domains -symptoms (PANSS total score, CGI-S), functioning/quality of life (QLS) and subjective well-being (SWN-K) -was predictive of COMBOUT. This fi nding was consistent with data reported by Lambert et al. [ 12 ] demonstrating that patients who achieved a pre-defi ned level of response across measures of symptoms (PANSS positive and negative scores, CGI-S), functioning (Scale of Occupational and Functional Assessment, SOFAs) and subjective well-being ( SWN-K ) at 4 weeks were predictive of a combined treatment outcome. Also consistent with Lambert et al. [ 12 ] , we found that early change in functioning and subjective well-being showed the strongest relationship in predicting COMBOUT in comparison to symptom severity. This fi nding is also consistent with the de Haan et al. study [ 34 ] in which early improvement among fi rst episode patients in subjective well-being, but not early improvement in PANSS, has been associated with enduring symptom remission [ 35 ] . These collective fi ndings highlight the potential value of assessing early improvement in functioning and subjective well-being as potential prognostic indicators of a patient's ultimate treatment response. Surprisingly, while inclusion of the MADRS revealed a significant relationship between depressive symptoms at baseline and COMBOUT at endpoint, a similar relationship was not observed between COMBOUT and early change in the MADRS at week 2. Previous fi ndings (from this dataset) revealed early improvement in MADRS scores during the initial 2 weeks of drug therapy [ 11 ] . These earlier fi ndings, though, were based only on those patients treated with risperidone for the entire 12 weeks. A separate group of patients (early non-responders to risperidone who were switched to olanzapine after 2 weeks), were excluded from that analysis. These patients were included in the current study. Of interest, these patients had shown signifi cantly greater improvement in the MADRS compared to early non-responders maintained on risperidone [ 6 ] and slightly diff erent results in model II.
We did not fi nd either baseline scores or early change scores in EPS measures of akathisia (Barnes Akathisia Scale), parkinsonism (Simpson-Angus Scale), or tardive dyskinesia (AIMS) to be predictive of COMBOUT. However, further study is needed to assess change in EPS status using categorical scores (and not only mean scores) across these measures. Another approachone that incorporates EPS measures scores into a single "Movement Disorder Index" -should be considered. A recent post-hoc analysis of a 1-year study of patients with schizophrenia [ 37 ] found that patients who experienced worsening of the Movement Disorder Index (which is based on the Barnes Akathisia Scale, the Simpson-Angus Scale and the AIMS, and use of antiparkinsonian agents) have evidenced signifi cantly poorer clinical and functional outcomes.
Limitations
▼
Equal weighting was used for the 5 outcome measures of interest -PANSS, CGI-S, MADRS, QLS and SWN-K. This approach seemed to be justifi ed since there are no data indicating that another method would be more appropriate. Switching a subset of patients from risperidone to olanzapine (as prescribed in the study design) may have confounded to some degree the prediction of COMBOUT. The potential value of using a ' combined treatment outcome' incorporating multiple endpoints as an approach to assess a multifaceted treatment outcome relevant to each patient's response and potential for recovery is worth further study.
Conclusions ▼
A broad multidimensional outcome measure, which incorporates psychopathology, functioning/quality of life and subjective well-being following 12 weeks of therapy, was predicted by a few baseline characteristics and by greater early improvement in most domains, particularly by early change in functioning/QOL and subjective well-being. Not focusing only on changes of (positive) psychopathology, but to include broader early clinical indicators may assist in identifying patients who require targeted interventions to help optimize their treatment outcomes. These fi ndings also lend further support to the value of the early response paradigm, which can be extended to most outcome measures.
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